Abstract
This month saw approvals for two products employing Halozyme’s Enhanze drug delivery technology (BMS’s Opdivo and Johnson and Johnson’s DARZALEX FASPRO®). A number of collaborations between industry partners and charities to fight the disease, including Duchenne muscular dystrophy and Epidermolysis Bullosa, have been announced. Successful clinical trial data was disclosed for products employing a wide variety of therapeutic delivery technologies including Perfuse Therapeutics intravitreal implant for glaucoma, Aspen Neurosciences precision delivery of an autologous dopaminergic neuronal precursor cell therapy for Parkinson’s disease and Resurge Therapeutics IntraProstatic Drug Elution (IPDE) therapy for prostate cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 701-707 |
| Number of pages | 7 |
| Journal | Therapeutic Delivery |
| Volume | 16 |
| Issue number | 8 |
| DOIs |
|
| Publication status | Published - 3 Aug 2025 |
Keywords
- Emerging technologies
- Glaucoma
- Oral delivery
- Parenteral delivery
- Parkinson’s Disease
- Personalized delivery
- Prostate Cancer
